Diagnostic and Prognostic Value of Serum Interleukin-10 in Patients with Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Background and Aim: Acute pancreatitis is the most common major complication of diagnostic and therapeutic endoscopic retrograde cholangiopancreatography [ERCP] occurring in 2% to 4% of low-risk patients and 8% to 20% of high-risk patients, with an overall average risk of approximately 10%. Cytokines, including IL-10 was also significantly higher in patients with severe acute pancreatitis. PEP was shown to be an ideal model for studying the time course of cytokine release during the initiation phase of pancreatitis. This study aimed to assess the diagnostic value of IL-10 in the early recognition of post-ERCP pancreatitis and also to evaluate its prognostic value in patients with post-ERCP pancreatitis (PEP). Subjects and Methods: Forty patients were included for endoscopic retrograde cholangiopancreatography. All patients were subjected to complete clinical evaluation and laboratory investigations. Twenty four hours after the procedure, serum levels of IL-10 were determined with use of commercial solid phase enzyme-linked immunosorbent assay (ELISA) kits. Results: Patients with pancreatic duct stenting had lesser frequency of PEP. There was significant correlation between vomiting, abdominal pain, and tenderness and PEP. There is no significant correlation between PEP and the IL-10 levels in our studied population.